United States - English - NLM (National Library of Medicine)

janssen biotech, inc. - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml - abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications - in patients undergoing percutaneous coronary intervention - in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours safety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been established. abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in clinical studies. because abciximab may increase the risk of bleeding, abciximab is contraindicated in the following clinical situations: - active internal bleeding - recent (within six weeks) gastrointestinal (gi) or genitourinary (gu) bleeding of clinical significance - history of cerebrovascular accident (cva) within two years, or cva with a significant residual neurological deficit - bleeding diathesis - administration of oral anticoagulan

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alemtuzumab, quantity: 30 mg - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections; polysorbate 80; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; sodium chloride; potassium chloride - the treatment of patients with b-cell chronic lymphocytic leukaemia (cll) who have relapsed after failure of two prior therapies.,mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (b-cll).

European Union - English - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - mabcampath is indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia (bcll) for whom fludarabine combination chemotherapy is not appropriate.

United States - English - NLM (National Library of Medicine)

eli lilly and company - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abciximab -

United States - English - NLM (National Library of Medicine)

abc technical solutions, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - - to decrease bacteria on the skin - recommended for repeated use

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ppg industries australia pty limited - thiram; cuprous oxide; zinc oxide; xylene - paint - thiram carbamate-dithiocarbamate active 45.0 g/l; cuprous oxide mineral-copper active 839.0 g/l; zinc oxide mineral-zinc active 244.0 g/l; xylene solvent other 163.0 g/l - antifouling - boat hull (refer to label) - fouling - for antifouling on boats

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - aconitum napellus; atropa belladonna; chloroform - liniment - active: aconitum napellus atropa belladonna chloroform

Australia - English - Department of Health (Therapeutic Goods Administration)

genzyme australasia pty ltd - alemtuzumab -

Canada - English - Health Canada

janssen inc - abciximab - solution - 2mg - abciximab 2mg - miscellaneous therapeutic agents